{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:48:09Z","timestamp":1762102089377,"version":"3.41.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T00:00:00Z","timestamp":1506643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T00:00:00Z","timestamp":1506643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s00393-017-0368-3","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T20:22:07Z","timestamp":1506716527000},"page":"57-62","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Autoimmunologische Reaktionen bei Immun-Checkpoint-Inhibitoren","Autoimmune reactions to immune checkpoint inhibitors"],"prefix":"10.1007","volume":"76","author":[{"given":"W.","family":"P\u00f6nisch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Alten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Baerwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,29]]},"reference":[{"key":"368_CR1","first-page":"190","volume":"35","author":"J Behling","year":"2017","unstructured":"Behling J, Schach A, Loquai C et al (2017) Immuncheckpoint-Inhibitoren. Immunvermittelte Nebenwirkungen. Arzneimitteltherapie 35:190\u2013198","journal-title":"Arzneimitteltherapie"},{"key":"368_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/annrheumdis-2017-211216","volume":"76","author":"R Belkhir","year":"2017","unstructured":"Belkhir R, Burel SL, Lambotte O et\u00a0al (2017) OP0004 Rheumatoid arthritis occuring after immune checkpoint inhibitors. Ann Rheum Dis 76:51\u201352","journal-title":"Ann. Rheum. Dis."},{"key":"368_CR3","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus Docetaxel in advanced Nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627\u20131639","journal-title":"N. Engl. J. Med."},{"key":"368_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros C, Tarhini A, Routier E et al (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13:473\u2013486","journal-title":"Nat Rev Clin Oncol"},{"key":"368_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123\u2013135","journal-title":"N. Engl. J. Med."},{"key":"368_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/annrheumdis-2016-209782","volume":"76","author":"C Calabrese","year":"2017","unstructured":"Calabrese C, Kirchner E, Kontzias A et\u00a0al (2017) OP0003 Rheumatic immune related adverse events of checkpoint therapy for cancer: case series of an emerging nosologic entity. Ann Rheum Dis 76:51\u201351","journal-title":"Ann. Rheum. Dis."},{"key":"368_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1186\/s13075-014-0469-1","volume":"16","author":"S Ceeraz","year":"2014","unstructured":"Ceeraz S, Nowak EC, Burns CM et\u00a0al (2014) Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. Arthritis Res Ther 16:469","journal-title":"Arthritis Res Ther"},{"key":"368_CR8","first-page":"559","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E et\u00a0al (2016) Management of immune checkpoint blockade dysimmune toxicities: a\u00a0collaborative position paper. Annals of oncology : official journal of the European Society for. Med Oncol 27:559\u2013574","journal-title":"Med Oncol"},{"key":"368_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/CJI.0000000000000060","volume":"38","author":"MM Chan","year":"2015","unstructured":"Chan MM, Kefford RF, Carlino M et al (2015) Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J\u00a0Immunother 38:37\u201339","journal-title":"J Immunother"},{"key":"368_CR10","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/annrheumdis-2017-eular.6532","volume":"76","author":"L Christ","year":"2017","unstructured":"Christ L, M\u00f6nch S, Hasmann S et\u00a0al (2017) FRI0606 Characteristics and treatment of new onset arthritis after checkpoint inhibitor therapy. Ann Rheum Dis 76:718\u2013718","journal-title":"Ann. Rheum. Dis."},{"key":"368_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00281-016-0595-8","volume":"39","author":"M Donia","year":"2017","unstructured":"Donia M, Pedersen M, Svane IM (2017) Cancer immunotherapy in patients with preexisting autoimmune disorders. Semin Immunopathol 39:333\u2013337","journal-title":"Semin Immunopathol"},{"key":"368_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3389\/fimmu.2014.00206","volume":"5","author":"YC Kong","year":"2014","unstructured":"Kong YC, Flynn JC (2014) Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1. Front Immunol 5:206","journal-title":"Front Immunol"},{"key":"368_CR13","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.18632\/oncotarget.2980","volume":"6","author":"JJ Luke","year":"2015","unstructured":"Luke JJ, Ott PA (2015) PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget 6:3479\u20133492","journal-title":"Oncotarget"},{"key":"368_CR14","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1093\/annonc\/mdt291","volume":"24","author":"D Mcdermott","year":"2013","unstructured":"Mcdermott D, Haanen J, Chen TT et al (2013) Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a\u00a0phase III trial (MDX010-20). Ann Oncol 24:2694\u20132698","journal-title":"Ann Oncol"},{"key":"368_CR15","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S et al (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28:368\u2013376","journal-title":"Ann Oncol"},{"key":"368_CR16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1634\/theoncologist.2016-0390","volume":"22","author":"J Naidoo","year":"2017","unstructured":"Naidoo J, Cappelli LC, Forde PM et\u00a0al (2017) Inflammatory arthritis: a newly recognized adverse event of immune checkpoint blockade. Oncologist 22:627\u2013630","journal-title":"Oncologist"},{"key":"368_CR17","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823\u20131833","journal-title":"N. Engl. J. Med."},{"key":"368_CR18","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/art.40043","volume":"69","author":"ME Suarez-Almazor","year":"2017","unstructured":"Suarez-Almazor ME, Kim ST, Abdel-Wahab N et al (2017) Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis Rheumatol 69:687\u2013699","journal-title":"Arthritis Rheumatol"},{"key":"368_CR19","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/annrheumdis-2017-eular.5461","volume":"76","author":"U Thanarajasingam","year":"2017","unstructured":"Thanarajasingam U, Pinkston O, Kottschade L et\u00a0al (2017) SAT0711 Checkpoint inhibitor therapy in patients with advanced malignancies and preexisting rheumatologic disease: the mayo clinic experience. Ann Rheum Dis 76:1044\u20131044","journal-title":"Ann. Rheum. Dis."},{"key":"368_CR20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/annrheumdis-2017-eular.3875","volume":"76","author":"L Tucker","year":"2017","unstructured":"Tucker L, Sacks S, Al-Mossawi H (2017) THU0562 Inflammatory joint disease triggered by immune checkpoint inhibitors. Ann Rheum Dis 76:419\u2013419","journal-title":"Ann. Rheum. Dis."},{"key":"368_CR21","first-page":"375","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a\u00a0randomised, controlled, open-label, phase 3 trial. The Lancet. Oncology 16:375\u2013384","journal-title":"Oncology"},{"key":"368_CR22","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M et al (2016) Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a\u00a0multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17:1283\u20131294","journal-title":"Lancet Oncol."}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-017-0368-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-017-0368-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-017-0368-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T23:23:51Z","timestamp":1750893831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-017-0368-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,29]]},"references-count":22,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["368"],"URL":"https:\/\/doi.org\/10.1007\/s00393-017-0368-3","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2017,9,29]]},"assertion":[{"value":"29 September 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Dieses Manuskript entstand auf Basis einer von Roche und Chugai unterst\u00fctzten Arbeitsgruppe, aber ohne jegliche Einflussnahme der Firmen auf das Ergebnis oder die Publikation. Der Beitrag ist Teil eines Supplements gesponsert von Chugai\/Roche.W.\u00a0P\u00f6nisch, R.\u00a0Alten und C.\u00a0Baerwald geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}